TD Cowen analyst Phil Nadeau raised the firm’s price target on Vertex Pharmaceuticals to $370 from $360 and keeps an Outperform rating on the shares. The firm said the company’s pipeline is maturing toward notable events over the next year including the potential approval/launch of exa-cel and results from the pivotal trials of 548 (pain) and the vanza triple (CF).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $390 from $380 at Bernstein
- Vertex Pharmaceuticals price target raised to $399 from $384 at Barclays
- Vertex Pharmaceuticals raises FY23 CF product revenue to $9.7B-$9.8B
- Vertex Pharmaceuticals reports Q2 EPS $3.52, consensus $3.88
- VRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Questions or Comments about the article? Write to editor@tipranks.com